These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10099914)

  • 1. Pharmacological treatment for hyperlipidaemia--the best preventive measure?
    Rosengren A; Swedberg K
    Eur Heart J; 1999 Feb; 20(4):245-6. PubMed ID: 10099914
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of hyperlipidaemia: postscript.
    Sum CF; Tan CE; Chew LS
    Singapore Med J; 1995 Oct; 36(5):538. PubMed ID: 8882543
    [No Abstract]   [Full Text] [Related]  

  • 3. [Secondary prevention of coronary heart disease with lipid lowering drugs. Evaluating outcome eliminates the controversy].
    Pedersen TR
    Internist (Berl); 1995 Dec; 36(12):1174-8. PubMed ID: 8567223
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipids and their role in coronary heart disease: what they do and how to manage them.
    Pradka LR
    Nurs Clin North Am; 2000 Dec; 35(4):981-91. PubMed ID: 11072283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The VA HDL intervention trial: clinical implications.
    Rubins HB; Collins D; Robins SJ
    Eur Heart J; 2000 Jul; 21(14):1113-5. PubMed ID: 10924289
    [No Abstract]   [Full Text] [Related]  

  • 6. Aggressive medical therapy for the prevention and treatment of coronary artery disease.
    Malloy MJ; Kane JP
    Adv Intern Med; 1997; 42():1-38. PubMed ID: 9048115
    [No Abstract]   [Full Text] [Related]  

  • 7. Dyslipidemia and coronary heart disease: management issues from Indian perspective.
    Gambhir DS; Gambhir JK; Sudha R
    Indian Heart J; 2000; 52(5):515-6, 617. PubMed ID: 11256772
    [No Abstract]   [Full Text] [Related]  

  • 8. When to treat raised lipids.
    Jolleys J
    Practitioner; 1999 Jun; 243(1599):510-3, 515-6. PubMed ID: 10476570
    [No Abstract]   [Full Text] [Related]  

  • 9. The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.
    Manuel DG; Tanuseputro P; Mustard CA; Schultz SE; Anderson GM; Ardal S; Alter DA; Laupacis A
    CMAJ; 2005 Apr; 172(8):1027-31. PubMed ID: 15824409
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapy and clinical trials.
    Curr Opin Lipidol; 1995 Dec; 6(6):B77-82. PubMed ID: 8750254
    [No Abstract]   [Full Text] [Related]  

  • 11. Strategies for optimizing lipid treatment outcomes.
    Spellman CW
    J Am Osteopath Assoc; 2003 Jan; 103(1 Suppl 1):S12-5. PubMed ID: 12572625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALLHAT: definitive answers or continuing uncertainty?
    Sever P;
    J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):3-5. PubMed ID: 12692746
    [No Abstract]   [Full Text] [Related]  

  • 13. [Analysis of reasons for discontinuation of treatment for dyslipidemia in secondary prevention of coronary heart disease].
    Tyszecka G
    Przegl Lek; 1999; 56(11):709-15. PubMed ID: 10800583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Milestone in the treatment of diabetic dyslipidemia: the DAIS Study].
    Forster T
    Orv Hetil; 2001 Jul; 142(29):1588-9. PubMed ID: 11494751
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of coronary arteriosclerosis depending on the nature of lipid metabolism disorders].
    Anisimov VE; Semavin IE
    Klin Med (Mosk); 1975 Jul; 53(7):66-9. PubMed ID: 1206996
    [No Abstract]   [Full Text] [Related]  

  • 16. [Eiconol effects on hemocoagulation in coronary heart disease patients].
    Dzhanashiia PK; Panchenko VM; Nazlukhanian SO; Chernova GI; Liutova LV; Semenov VA; Korneenkov VK; Perekrestova EI; Nurmukhamedov SA; Andreenko GI
    Klin Med (Mosk); 1997; 75(10):55-7. PubMed ID: 9490343
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of hyperlipidemia with a new drug, tibric acid].
    Carmena R; González R Florez J; Sanchis J
    Rev Clin Esp; 1976 Jul; 142(2):151-5. PubMed ID: 788065
    [No Abstract]   [Full Text] [Related]  

  • 18. Halofenate: an effective hypolipemia- and hypouricemia-inducing drug.
    Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
    Curr Ther Res Clin Exp; 1973 Dec; 15(12):902-6. PubMed ID: 4203573
    [No Abstract]   [Full Text] [Related]  

  • 19. Dietary and pharmacologic therapy of the lipid risk factors. AMA Council on Scientific Affairs.
    Conn Med; 1985 May; 49(5):321-8. PubMed ID: 3891221
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)?
    Sherrod JP; Krist A
    J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.